NEW YORK (GenomeWeb) – Metamark today announced that its Cambridge, Mass., laboratory has received accreditation from the College of American Pathologists.
The lab will be the primary facility for processing the company's ProMark protein-biopsy test to aid physicians and prostate cancer patients select the most appropriate treatment options. The test generates a score and is targeted to the 85 percent of patients with biopsy Gleason grades of 3+3 or 3+4 for whom current standard-of-care tests may offer unclear guidance, the Cambridge-based firm said.
The lab is also CLIA certified, and earlier this year Metamark's CLIA-accredited labs in Collegeville, Penn., and Augusta, Ga., also received accreditation by CAP.